Department of Viral Glycoproteins, Institute of Biochemistry of the Romanian Academy, Splaiul Independentei, 296, Sector 6, Bucharest, 060031, Romania,
Adv Exp Med Biol. 2014;806:453-81. doi: 10.1007/978-3-319-06068-2_22.
Infection with Hepatitis B virus (HBV) is the most common cause of liver disease in the world. Infection becomes chronic in up to 10 % of adults, with severe consequences on liver function, including inflammation, fibrosis, cirrhosis, and eventually hepatocellular carcinoma (HCC). HCC is a fast progressing disease causing the death of approximately one million patients annually; current treatment has very limited success, mainly due to late-stage diagnosis and poor screening methodologies. Therefore, unraveling the complex HBV-host cell interactions during progression of the disease is of crucial importance, not only to understand the mechanisms underlying carcinogenesis, but importantly, for the development of new biomarkers for prognostic and early diagnosis. This is an area of research strongly influenced by proteomic studies, which have benefited in the last decade from major technical improvements in accuracy of quantification and sensitivity, large-scale analysis of low-abundant proteins, such as those from clinical samples being now possible and widely applied. This work is a critical review of the impact of the proteomic studies on our current understanding of HBV-associated pathogenesis, diagnostics, and treatment.
乙型肝炎病毒 (HBV) 感染是世界上最常见的肝脏疾病病因。在多达 10%的成年人中，感染会发展为慢性感染，导致严重的肝功能后果，包括炎症、纤维化、肝硬化，最终导致肝细胞癌 (HCC)。HCC 是一种快速进展的疾病，每年导致约 100 万人死亡；目前的治疗方法成功率非常有限，主要是因为诊断较晚和筛查方法不佳。因此，揭示疾病进展过程中乙型肝炎病毒-宿主细胞相互作用的复杂机制非常重要，这不仅有助于了解致癌机制，而且重要的是，为预后和早期诊断开发新的生物标志物。这是一个受到蛋白质组学研究强烈影响的研究领域，在过去十年中，定量和灵敏度的准确性、对低丰度蛋白质（如来自临床样本的蛋白质）的大规模分析等方面取得了重大技术进步，现在已经可以广泛应用。这项工作是对蛋白质组学研究对我们目前对乙型肝炎病毒相关发病机制、诊断和治疗的理解的影响的批判性回顾。
